Clinical Trials Logo

Neuroendocrine Breast Tumor clinical trials

View clinical trials related to Neuroendocrine Breast Tumor.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04276597 Withdrawn - Clinical trials for Neuroendocrine Tumors

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

PUTNET
Start date: March 4, 2020
Phase: Phase 2
Study type: Interventional

Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other non-.GEP-NET. The treatment regimen will consist of 4 doses of 200 (±10%) mCi 177Lu-DOTATOC administered at 8+/- 1-week intervals.